MDNAF News and Press, Mandatum Pankki Oyj From 03/31/20

Medicenna Therapeutics Corp. [TSX:MDNA] ( OTCQB:MDNAF ) is a Toronto based clinical-stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines. Superkines can be engineered as short or long-acting therapeutics or fused with cell-killing protei...

Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study Canada NewsWire TORONTO and HOUSTON, March 25, 2020 Conference call and webcast today at 10:00AM EST to discuss MDNA19 results with pre-clinical experts showing robust im...

Medicenna Announces Closing of Public Offering of $35 Million Canada NewsWire TORONTO and HOUSTON, March 17, 2020 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , March 17, 2020 /CNW/ - Medicenna T...

Medicenna Announces Intention to File Final Short Form Prospectus Canada NewsWire TORONTO and HOUSTON, March 12, 2020 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , March 12, 2020 /CNW/ - Medice...

Medicenna Therapeutics Corp. [TSX:MDNA] (MDNAF) is a Toronto based clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™. Superkines can be engineered as short or long-acting therapeutics or fused with cell killing protei...

Medicenna Reports Third Quarter Fiscal 2020 Financial Results Canada NewsWire TORONTO and HOUSTON, Feb. 13, 2020 TORONTO and HOUSTON , Feb. 13, 2020 /CNW/ - Medicenna Therapeutics Corp. (" Medicenna " or the " Company ") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immun...

Phoenix, Arizona--(Newsfile Corp. - January 21, 2020) - The Stock Day Podcast welcomed Medicenna Therapeutics Corp. (TSX: MDNA) (OTCQB: MDNAF) ("the Company"), a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versio...

Survival improvement of over 150% seen in MDNA55 subjects compared to a Synthetic Control Arm TORONTO and HOUSTON , Jan 13, 2020 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, to...

Medicenna Receives $1.3 Million Through Early Warrant Exercises Canada NewsWire TORONTO and HOUSTON, Jan. 8, 2020 TORONTO and HOUSTON , Jan. 8, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immu...

-  MDNA55 achieves up to 5 fold increase in 12 month survival rate in aggressive, chemotherapy resistant glioblastoma when compared to approved therapies TORONTO and HOUSTON , Dec. 12, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX...